These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38094112)

  • 21. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
    Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
    ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The "Hemodynamic Recovery".
    Romano G; Vitale G; Ajello L; Agnese V; Bellavia D; Caccamo G; Corrado E; Di Gesaro G; Falletta C; La Franca E; Minà C; Storniolo SA; Sarullo FM; Clemenza F
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
    Witte KK; Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Fonseca C; Lonn E; Noè A; Schwende H; Butylin D; Chiang Y; Pascual-Figal D;
    ESC Heart Fail; 2023 Feb; 10(1):80-89. PubMed ID: 36125177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis.
    Chen WW; Jiang J; Gao J; Zhang XZ; Li YM; Liu YL; Dang HQ
    Clin Cardiol; 2023 Mar; 46(3):296-303. PubMed ID: 36648084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
    Chen W; Liu Y; Li Y; Dang H
    ESC Heart Fail; 2021 Oct; 8(5):3783-3790. PubMed ID: 34155812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
    Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
    Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
    ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
    Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
    Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
    Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.